Skip to main content

Population Pharmacokinetic Modeling of Guanfacine in Pediatric Patients

Abstract

Introduction

The population pharmacokinetics of guanfacine extended release were characterized in pediatric patients aged 6–17 years using NONMEM and evaluated by predictive check and bootstrap.

Methods

Data were described using a one-compartment model. A covariate modeling approach that emphasized parameter estimation rather than stepwise hypothesis testing was implemented. A nonparametric bootstrap procedure and a predictive check method were used to evaluate the final model and parameter estimates.

Results

Typical population pharmacokinetic parameters (95 % confidence interval), given the reference covariates (Caucasian, male, age 12 years, weight 50 kg), were 33.1 (30.2–36.4) L/h for apparent clearance (CL/F), 804 (703–900) L for apparent volume of distribution, 0.552 (0.437–0.670) h−1 for the absorption rate constant, and 0.651 (0.608–0.697) h for absorption lag time.

Discussion

The pharmacokinetics of guanfacine are similar in pediatric patients compared with adults when appropriately scaled by patient weight. The main predictor of guanfacine exposure, as determined by a change in CL/F, was weight. Effects of the other covariates (age, sex, and race) on CL/F were estimated with reasonable precision; however, the additional effects of age, sex, and race can be considered to have little to no clinical relevance.

This is a preview of subscription content, access via your institution.

Fig. 1
Fig. 2
Fig. 3

References

  1. 1.

    National Institute of Mental Health. Attention deficit hyperactivity disorder (ADHD). US Department of Health and Human Services; 2008.

  2. 2.

    Biederman J, Faraone SV. Attention-deficit hyperactivity disorder. Lancet. 2005;366(9481):237–48.

    PubMed  Article  Google Scholar 

  3. 3.

    Kratochvil C. New ADHD treatment options on the horizon. Adv Stud Med. 2002;2(25):915–8.

    Google Scholar 

  4. 4.

    Scahill L, Chappell PB, Kim YS, et al. A placebo-controlled study of guanfacine in the treatment of children with tic disorders and attention deficit hyperactivity disorder. Am J Psychiatry. 2001;158(7):1067–74.

    CAS  PubMed  Article  Google Scholar 

  5. 5.

    Cantwell DP. Attention deficit disorder: a review of the past 10 years. J Am Acad Child Adolesc Psychiatry. 1996;35(8):978–87.

    CAS  PubMed  Article  Google Scholar 

  6. 6.

    INTUNIV® (guanfacine) extended-release tablets [package insert]. Wayne, PA: Shire Pharmaceuticals LLC.

  7. 7.

    Boellner SW, Pennick M, Fiske K, Lyne A, Shojaei A. Pharmacokinetics of a guanfacine extended-release formulation in children and adolescents with attention-deficit-hyperactivity disorder. Pharmacotherapy. 2007;27(9):1253–62.

    CAS  PubMed  Article  Google Scholar 

  8. 8.

    Kiechel JR. Pharmacokinetics and metabolism of guanfacine in man: a review. Br J Clin Pharmacol. 1980;10(Suppl 1):25S–32S.

    PubMed Central  PubMed  Article  Google Scholar 

  9. 9.

    Carchman SH, Crowe JT Jr, Wright GJ. The bioavailability and pharmacokinetics of guanfacine after oral and intravenous administration to healthy volunteers. J Clin Pharmacol. 1987;27(10):762–7.

    CAS  PubMed  Article  Google Scholar 

  10. 10.

    Kollins SH, Lopez FA, Vince BD, et al. Psychomotor functioning and alertness with guanfacine extended release in subjects with attention-deficit/hyperactivity disorder. J Child Adolesc Psychopharmacol. 2011;21(2):111–20.

    PubMed  Article  Google Scholar 

  11. 11.

    Beal SL, Sheiner LB, Boeckmann AJ. NONMEM Users Guide: Part I–VII, (1989–2006). Ellicott City, MD: Icon Development Solutions; 2006.

    Google Scholar 

  12. 12.

    Anderson BJ, Woollard GA, Holford NH. A model for size and age changes in the pharmacokinetics of paracetamol in neonates, infants and children. Br J Clin Pharmacol. 2000;50(2):125–34.

    CAS  PubMed Central  PubMed  Article  Google Scholar 

  13. 13.

    Anderson BJ, Holford NH, Woollard GA, Chan PL. Paracetamol plasma and cerebrospinal fluid pharmacokinetics in children. Br J Clin Pharmacol. 1998;46(3):237–43.

    CAS  PubMed Central  PubMed  Article  Google Scholar 

  14. 14.

    Anderson BJ, McKee AD, Holford NH. Size, myths and the clinical pharmacokinetics of analgesia in paediatric patients. Clin Pharmacokinet. 1997;33(5):313–27.

    CAS  PubMed  Article  Google Scholar 

  15. 15.

    Holford NH. A size standard for pharmacokinetics. Clin Pharmacokinet. 1996;30(5):329–32.

    CAS  PubMed  Article  Google Scholar 

  16. 16.

    Efron B. Missing data, imputation, and the bootstrap. J Am Stat Assoc. 1994;89(426):463–79.

    Article  Google Scholar 

  17. 17.

    Parke J, Holford NH, Charles BG. A procedure for generating bootstrap samples for the validation of nonlinear mixed-effects population models. Comput Methods Programs Biomed. 1999;59(1):19–29.

    CAS  PubMed  Article  Google Scholar 

  18. 18.

    Ette EI, Onyiah LC. Estimating inestimable standard errors in population pharmacokinetic studies: the bootstrap with Winsorization. Eur J Drug Metab Pharmacokinet. 2002;27(3):213–24.

    CAS  PubMed  Article  Google Scholar 

  19. 19.

    Yano Y, Beal SL, Sheiner LB. Evaluating pharmacokinetic/pharmacodynamic models using the posterior predictive check. J Pharmacokinet Pharmacodyn. 2001;28(2):171–92.

    CAS  PubMed  Article  Google Scholar 

  20. 20.

    Swearingen D, Pennick M, Shojaei A, Lyne A, Fiske K. A phase I, randomized, open-label, crossover study of the single-dose pharmacokinetic properties of guanfacine extended-release 1-, 2-, and 4-mg tablets in healthy adults. Clin Ther. 2007;29(4):617–25.

    CAS  PubMed  Article  Google Scholar 

  21. 21.

    Mahmood I. Prediction of drug clearance in children from adults: a comparison of several allometric methods. Br J Clin Pharmacol. 2006;61(5):545–57.

    CAS  PubMed Central  PubMed  Article  Google Scholar 

Download references

Acknowledgments

Funding for this research was provided to Metrum by Shire Development LLC. Melissa Brunckhorst, Ph.D., from MedErgy, provided editorial assistance in formatting, proofreading, and copy editing. This support was funded by Shire. Although the sponsor was involved in the design, collection, analysis, interpretation, and fact checking of information, the content of this manuscript, the ultimate interpretation, and the decision to submit it for publication in Clinical Pharmacokinetics were made by all the authors independently.

Financial disclosure

WK and MRG are employees of Metrum Research Group LLC, which received funding from Shire Development LLC for this study. JE and MC are employees of Shire Development LLC and hold stock/stock options in Shire.

Ethical standard

The studies included in the analyses were approved by an ethics committee or institutional review board and were conducted in accordance with the current revision of the Declaration of Helsinki.

Author information

Affiliations

Authors

Corresponding author

Correspondence to William Knebel.

Electronic supplementary material

Below is the link to the electronic supplementary material.

40262_2015_245_MOESM1_ESM.tiff

Supplemental Fig. 1. Predictive check for median guanfacine concentrations with distributions of simulated median concentrations within each individual (Cmed) compared to the actual observed distribution of Cmed values from the population pharmacokinetic database. Quantile-quantile plots for each of the 1000 simulation replicates are depicted by a grey dashed line and are overlaid on this plot. The black solid line represents a reference line of identity.(TIFF 1054 kb)

Rights and permissions

Reprints and Permissions

About this article

Verify currency and authenticity via CrossMark

Cite this article

Knebel, W., Corcoran, M., Ermer, J. et al. Population Pharmacokinetic Modeling of Guanfacine in Pediatric Patients. Clin Pharmacokinet 54, 875–883 (2015). https://doi.org/10.1007/s40262-015-0245-7

Download citation

Keywords

  • Guanfacine
  • Allometric Model
  • Reference Weight
  • Nonparametric Bootstrap Procedure
  • Reference Covariates